Perspective Therapeutics (NYSEAMERICAN:CATX) Given Outperform Rating at Lifesci Capital

Lifesci Capital restated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research note issued to investors on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

CATX has been the topic of a number of other research reports. Oppenheimer restated an outperform rating and issued a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley upped their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a buy rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Trading Down 4.3 %

NYSEAMERICAN CATX opened at 1.76 on Monday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -17.60 and a beta of 1.43. Perspective Therapeutics has a fifty-two week low of 0.21 and a fifty-two week high of 1.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insiders Place Their Bets

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Perkins Capital Management Inc. purchased a new stake in Perspective Therapeutics during the third quarter worth $731,000. HighTower Advisors LLC purchased a new position in Perspective Therapeutics in the third quarter valued at about $314,000. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Perspective Therapeutics in the third quarter worth about $42,000. Finally, RIA Advisory Group LLC lifted its position in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after buying an additional 99,293 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.